QLT Shows Off Its Assets In Hopes Of Attracting A Suitor
This article was originally published in The Pink Sheet Daily
Executive Summary
The Canadian biotech has put itself on the block after a year of changes that have transformed the company from a commercial-stage entity with pipeline assets to a one-drug tax play.
You may also be interested in...
QLT Gets New Lease On Life With Multi-Pronged Deals
The Canadian drug developer will be in a position to advance its lead retinoid asset and be an acquirer of choice, according to management, after completing a series of deals, including the acquisition of InSite Vision and an investment in a new company, Aralez Pharmaceuticals.
Auxilium Accepts Endo Offer, Dumps QLT Merger Plans
Endo seals the deal with Auxilium in a $2.6 billion acquisition that will add to its men’s health business and won’t prevent it from continuing on its M&A spree.
Auxilium Rejects Endo, But Is It Making A Play For More Cash?
Negotiations are likely to kick into high gear now that Auxilium officially has rejected Endo’s first offer of $2.2 billion. Auxilium is sticking to its QLT commitment, but the transaction holds little more than a tax-inversion play for the biotech.